DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP046: Mid- to Long-term Stability and Associated Prognostic Factors of Adalimumab Treatment for 1189 Patients with Crohn’s Disease: A Multicenter Cohort StudyECCO'16 DOP 2016
1
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7ECCO'16 DOP 2016
1
DOP049: Efficacy and safety of golimumab induction for moderate to severe ulcerative colitis in the United Kingdom: Results from the GO-COLITIS studyECCO'16 DOP 2016
1
DOP057: Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn’s disease (BELCRO)ECCO'16 DOP 2016
1
DOP059: Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn’s Disease with Complications or Failure of Medical TreatmentECCO'16 DOP 2016
1
DOP063: Measurement of Endoscopic Severity in a Crohn's Disease Multi-Centre Pediatric Inception Cohort: Poor correlation of SES-CD with PCDAIECCO'16 DOP 2016
1
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabECCO'16 DOP 2016
1
DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulatorsECCO'16 DOP 2016
1
DOP066: Disappearance of Anti-drug Antibodies to Infliximab and Adalimumab after Addition of an Immunomodulator in Patients with Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a Tertiary IBD CentreECCO'16 DOP 2016
1
DOP069: Dose optimization using drug and antibody levels can benefit 50% patients prescribed anti TNF therapy compared to empiric dose adjustmentECCO'16 DOP 2016
1